This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2018-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018-2019
Title: Jane Brown: Innovator in Heterocyclic Compounds
Introduction
Jane Brown is a distinguished inventor based in Bingham, GB. She has made significant contributions to the field of medicinal chemistry, particularly in the development of heterocyclic compounds. With a total of two patents to her name, her work focuses on innovative solutions for treating various medical conditions.
Latest Patents
Jane's latest patents include "Heterocyclic Compounds and Methods for Their Use" and "Pyrrolidine Derivatives as Angiotensin II Type 2 Antagonists." The first patent relates to compounds that are useful for antagonizing the angiotensin II Type 2 (AT) receptor. This invention addresses disorders associated with AT receptor function, including neuropathic pain and inflammatory pain. The second patent focuses on heterocyclic angiotensin II type 2 receptor antagonists, which are designed for the treatment of neuropathic or inflammatory pain.
Career Highlights
Jane Brown is currently employed at Novartis AG, where she continues to advance her research in pharmacology. Her work has been instrumental in developing new therapeutic approaches that target complex medical conditions.
Collaborations
Some of her notable coworkers include Thomas David McCarthy and Alan Naylor, who have collaborated with her on various projects within the company.
Conclusion
Jane Brown's innovative work in the field of heterocyclic compounds showcases her commitment to advancing medical science. Her contributions have the potential to significantly impact the treatment of pain-related disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile